Perran Fulden Yumuk Selected Research

Neoplasms (Cancer)

9/2023	Assessment of chemotherapy-related educational needs of colorectal cancer patients.
7/2023	The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
5/2023	Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.
7/2022	Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy.
1/2022	Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders.
1/2021	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
1/2021	A rare case of gastric cancer with bilateral breast metastasis during pregnancy.
11/2020	Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG).
10/2020	Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.
6/2020	How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Perran Fulden Yumuk Research Topics

Disease

14	Neoplasms (Cancer) 09/2023 - 01/2004
11	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023 - 05/2010
9	Breast Neoplasms (Breast Cancer) 07/2022 - 06/2011
6	Colorectal Neoplasms (Colorectal Cancer) 09/2023 - 03/2005
2	Stomach Neoplasms (Stomach Cancer) 04/2023 - 01/2021
2	Adenocarcinoma 04/2023 - 12/2020
2	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2021
2	Disease Progression 01/2020 - 01/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2023
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2022
1	Prostatic Neoplasms (Prostate Cancer) 11/2022
1	Residual Neoplasm 05/2022
1	Lymphatic Metastasis 01/2022
1	Thrombocytopenia (Thrombopenia) 07/2021
1	Anaplastic Thyroid Carcinoma 01/2021
1	Epithelioid Hemangioendothelioma 10/2020
1	Inflammation (Inflammations) 09/2020
1	Insulin Resistance 09/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2020
1	Ductal Carcinoma 09/2020
1	Anorexia 01/2020
1	Neuralgia (Stump Neuralgia) 01/2020
1	Pain (Aches) 01/2020
1	Circulating Neoplastic Cells 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Glioma (Gliomas) 01/2020
1	Fatigue 01/2020
1	Pathologic Complete Response 01/2019
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019
1	Chordoma 08/2018
1	Gingival Hyperplasia 06/2016
1	Malignant Mesothelioma 02/2016
1	Weight Gain 06/2011

Drug/Important Bio-Agent (IBA)

6	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2020
3	AlbuminsIBA 01/2022 - 01/2020
2	Anaplastic Lymphoma KinaseIBA 11/2023 - 06/2020
2	alectinibIBA 07/2023 - 01/2022
2	CrizotinibIBA 07/2023 - 06/2020
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 05/2023 - 05/2022
2	Tyrosine Kinase InhibitorsIBA 02/2023 - 01/2022
2	AfatinibIBA 02/2023 - 12/2020
2	B7-H1 AntigenIBA 01/2021 - 08/2020
2	ErbB Receptors (EGF Receptor)IBA 12/2020 - 01/2020
2	Hormones (Hormone)IBA 09/2020 - 01/2020
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2023
1	atezolizumabIBA 12/2022
1	gallium 68 PSMA-11IBA 11/2022
1	beta-Aminoethyl Isothiourea (AET)IBA 07/2022
1	osimertinibIBA 06/2022
1	human ERBB2 proteinIBA 01/2022
1	Trastuzumab (Herceptin)FDA Link 01/2022
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022
1	Ado-Trastuzumab EmtansineIBA 07/2021
1	TransferasesIBA 07/2021
1	dabrafenibIBA 01/2021
1	pembrolizumabIBA 01/2021
1	IpilimumabIBA 01/2021
1	trametinibIBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2020
1	AntibodiesIBA 10/2020
1	Epidermal Growth Factor (EGF)IBA 09/2020
1	Blood Glucose (Blood Sugar)IBA 09/2020
1	Glucose (Dextrose)FDA LinkGeneric 09/2020
1	Insulin (Novolin)FDA Link 09/2020
1	regorafenibIBA 01/2020
1	C-Reactive ProteinIBA 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	Bevacizumab (Avastin)FDA Link 07/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	Carboplatin (JM8)FDA LinkGeneric 01/2019
1	VemurafenibIBA 06/2016
1	AnthracyclinesIBA 06/2011
1	taxaneIBA 06/2011
1	Docetaxel (Taxotere)FDA Link 05/2010
1	Cisplatin (Platino)FDA LinkGeneric 05/2010

Therapy/Procedure

10	Drug Therapy (Chemotherapy) 09/2023 - 05/2010
9	Therapeutics 07/2022 - 06/2011
5	Neoadjuvant Therapy 04/2023 - 01/2019
2	Adjuvant Chemotherapy 06/2011 - 03/2005
1	Castration 11/2022
1	Gastrectomy 01/2021
1	Chemoradiotherapy 12/2020
1	Palliative Care (Palliative Therapy) 11/2020
1	Molecular Targeted Therapy 08/2018
1	Pneumonectomy (Lung Volume Reduction) 02/2016
1	Orchiectomy (Orchidectomy) 01/2004
1	Prostatectomy (Retropubic Prostatectomy) 01/2004
1	Mastectomy (Mammectomy) 01/2004
1	Ovariectomy (Oophorectomy) 01/2004